Kiniksa Pharmaceuticals International, plc (NASDAQ:KNSA) Receives Average Recommendation of “Moderate Buy” from Brokerages

Shares of Kiniksa Pharmaceuticals International, plc (NASDAQ:KNSA) have been given an average recommendation of “Moderate Buy” by the nine ratings firms that are presently covering the company, Marketbeat Ratings reports. Two research analysts have rated the stock with a hold rating and seven have issued a buy rating on the company. The average 1-year price objective among analysts that have covered the stock in the last year is $93.14.

KNSA has been the topic of several recent analyst reports. Wedbush upped their price objective on shares of Kiniksa Pharmaceuticals International from $72.00 to $99.00 and gave the stock an “outperform” rating in a report on Wednesday, July 29th. Weiss Ratings downgraded shares of Kiniksa Pharmaceuticals International from a “buy (b-)” rating to a “hold (c+)” rating in a report on Thursday, August 13th. Wells Fargo & Company initiated coverage on Kiniksa Pharmaceuticals International in a research report on Wednesday. They issued an “overweight” rating and a $87.00 target price on the stock. The Goldman Sachs Group upped their price target on Kiniksa Pharmaceuticals International from $75.00 to $90.00 and gave the stock a “buy” rating in a research note on Thursday, July 30th. Finally, JPMorgan Chase & Co. raised their price target on Kiniksa Pharmaceuticals International from $72.00 to $107.00 and gave the stock an “overweight” rating in a research report on Wednesday, July 29th.

Insider Activity

In related news, CAO Michael Megna sold 4,600 shares of the stock in a transaction dated Thursday, September 3rd. The stock was sold at an average price of $80.30, for a total transaction of $369,380.00. Following the transaction, the chief accounting officer owned 29,062 shares of the company’s stock, valued at approximately $2,333,678.60. This represents a 13.67% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director G. Bradley Cole sold 3,673 shares of the firm’s stock in a transaction dated Wednesday, July 29th. The shares were sold at an average price of $81.43, for a total value of $299,092.39. Following the transaction, the director owned 11,672 shares of the company’s stock, valued at $950,450.96. This trade represents a 23.94% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. 51.98% of the stock is currently owned by corporate insiders.

Institutional Inflows and Outflows

A number of institutional investors have recently made changes to their positions in the business. Bank of America Corp DE grew its position in shares of Kiniksa Pharmaceuticals International by 220.9% during the first quarter. Bank of America Corp DE now owns 735,940 shares of the company’s stock worth $35,436,000 after buying an additional 506,576 shares in the last quarter. Spruce Street Capital LP acquired a new stake in Kiniksa Pharmaceuticals International in the fourth quarter valued at approximately $17,943,000. Rubric Capital Management LP raised its holdings in Kiniksa Pharmaceuticals International by 12.7% in the first quarter. Rubric Capital Management LP now owns 3,750,000 shares of the company’s stock valued at $180,562,000 after acquiring an additional 421,347 shares in the last quarter. Janus Henderson Group PLC lifted its stake in Kiniksa Pharmaceuticals International by 213.5% in the first quarter. Janus Henderson Group PLC now owns 481,023 shares of the company’s stock worth $23,197,000 after acquiring an additional 327,595 shares during the last quarter. Finally, BNP Paribas Financial Markets lifted its stake in Kiniksa Pharmaceuticals International by 27.3% in the fourth quarter. BNP Paribas Financial Markets now owns 831,777 shares of the company’s stock worth $34,311,000 after acquiring an additional 178,366 shares during the last quarter. Institutional investors and hedge funds own 53.95% of the company’s stock.

Kiniksa Pharmaceuticals International Trading Up 0.8%

Shares of KNSA opened at $75.22 on Friday. The company’s 50-day moving average price is $77.04 and its 200 day moving average price is $61.57. Kiniksa Pharmaceuticals International has a 12-month low of $35.20 and a 12-month high of $82.94. The firm has a market cap of $5.87 billion, a P/E ratio of 77.55 and a beta of 0.04.

Kiniksa Pharmaceuticals International (NASDAQ:KNSA) last announced its earnings results on Tuesday, July 28th. The company reported $0.30 earnings per share for the quarter, hitting the consensus estimate of $0.30. Kiniksa Pharmaceuticals International had a net margin of 9.59% and a return on equity of 13.65%. The company had revenue of $243.60 million during the quarter, compared to analyst estimates of $226.49 million. Equities research analysts forecast that Kiniksa Pharmaceuticals International will post 1.37 earnings per share for the current year.

About Kiniksa Pharmaceuticals International

Kiniksa Pharmaceuticals International, Ltd. is a biopharmaceutical company focused on developing and commercializing therapies for patients with debilitating diseases, including conditions driven by immune-system and inflammatory responses. The company’s strategy centers on targeted medicines intended to address significant unmet medical needs in specialty markets.

Kiniksa’s primary commercial product is ARCALYST (rilonacept), an interleukin-1 blocker. In the United States, ARCALYST is approved for the treatment of recurrent pericarditis and for reducing the risk of recurrence in adults and children age 12 and older.